Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $11,768.30 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 1,718 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $6.85, for a total transaction of $11,768.30. Following the completion of the sale, the insider owned 2,846,592 shares in the company, valued at $19,499,155.20. The trade was a 0.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Entrada Therapeutics Trading Down 2.5%

Shares of NASDAQ TRDA opened at $7.06 on Thursday. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $16.45. The company has a market cap of $274.07 million, a PE ratio of -1.77 and a beta of -0.26. The stock has a 50 day simple moving average of $6.86 and a 200-day simple moving average of $9.77.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.03. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%.The firm had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.23 million. Sell-side analysts forecast that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TRDA. Roth Capital set a $10.00 target price on shares of Entrada Therapeutics in a research report on Friday, May 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Guggenheim reduced their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Finally, Weiss Ratings cut shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Entrada Therapeutics has a consensus rating of “Hold” and an average price target of $17.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Baker BROS. Advisors LP raised its holdings in shares of Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after purchasing an additional 206,911 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Entrada Therapeutics by 735.0% during the third quarter. JPMorgan Chase & Co. now owns 133,878 shares of the company’s stock worth $776,000 after buying an additional 117,844 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock worth $176,000 after buying an additional 1,560 shares during the last quarter. Quantinno Capital Management LP grew its position in Entrada Therapeutics by 4.9% in the first quarter. Quantinno Capital Management LP now owns 71,018 shares of the company’s stock worth $896,000 after buying an additional 3,301 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Entrada Therapeutics by 18.7% in the first quarter. Dimensional Fund Advisors LP now owns 324,471 shares of the company’s stock valued at $4,092,000 after buying an additional 51,093 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.